Dysfunctional endothelial progenitor cells in patients with Hodgkin's lymphoma in complete remission.
Hodgkin’s lymphoma
cardiovascular disease
endothelial progenitor cells
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
22
09
2018
accepted:
19
11
2018
pubmed:
15
12
2018
medline:
4
3
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
Patients with a history of Hodgkin's lymphoma (HL) are at increased long-term risk of cardiovascular morbidity and mortality. Studies report an association between the pathophysiology of coronary artery disease (CAD) and levels of circulating endothelial progenitor cells (EPC), which play an essential role in vascular injury repair. The aim of the present study was to investigate the potential involvement of abnormal EPC level or function in the CAD risk of survivors of HL in remission. EPCs were isolated from peripheral blood samples drawn from 4 groups of patients aged 20-50 years with no history of CAD: 17 patients with HL who had been in complete remission for at least 2 years, four newly diagnosed patients with HL before treatment, 28 patients with diabetes all attending a tertiary medical center, and 16 healthy individuals. Levels of EPC surface markers were measured by flow cytometry, and EPC function was evaluated by the number of colony-forming units (CFUs) and MTT assay. Levels of circulating CD34(+)/VEGFR2(+) and CD133(+)/VEGFR2(+) were significantly higher in the newly diagnosed untreated patients with HL compared to the patients with HL in remission (P = 0.03 and P = 0.005, respectively), in the patients in remission compared to the patients with diabetes (P = 0.011 and P < 0.001, respectively), and in the patients in remission compared to the healthy individuals (P = 0.08 and P = 0.003, respectively). The analysis of cell viability and the number of colony-forming units in the patients with HL in remission yielded significant differences from the healthy group (P = 0.005 and P < 0.001, respectively) but not from either the newly diagnosed patients with HL or the diabetic patients. These results suggest that patients in complete remission of HL for at least 2 years have an abnormal EPC profile characterized by high circulating levels but attenuated function.
Sections du résumé
BACKGROUND
Patients with a history of Hodgkin's lymphoma (HL) are at increased long-term risk of cardiovascular morbidity and mortality. Studies report an association between the pathophysiology of coronary artery disease (CAD) and levels of circulating endothelial progenitor cells (EPC), which play an essential role in vascular injury repair. The aim of the present study was to investigate the potential involvement of abnormal EPC level or function in the CAD risk of survivors of HL in remission.
METHODS
EPCs were isolated from peripheral blood samples drawn from 4 groups of patients aged 20-50 years with no history of CAD: 17 patients with HL who had been in complete remission for at least 2 years, four newly diagnosed patients with HL before treatment, 28 patients with diabetes all attending a tertiary medical center, and 16 healthy individuals. Levels of EPC surface markers were measured by flow cytometry, and EPC function was evaluated by the number of colony-forming units (CFUs) and MTT assay.
RESULTS
Levels of circulating CD34(+)/VEGFR2(+) and CD133(+)/VEGFR2(+) were significantly higher in the newly diagnosed untreated patients with HL compared to the patients with HL in remission (P = 0.03 and P = 0.005, respectively), in the patients in remission compared to the patients with diabetes (P = 0.011 and P < 0.001, respectively), and in the patients in remission compared to the healthy individuals (P = 0.08 and P = 0.003, respectively). The analysis of cell viability and the number of colony-forming units in the patients with HL in remission yielded significant differences from the healthy group (P = 0.005 and P < 0.001, respectively) but not from either the newly diagnosed patients with HL or the diabetic patients.
CONCLUSIONS
These results suggest that patients in complete remission of HL for at least 2 years have an abnormal EPC profile characterized by high circulating levels but attenuated function.
Identifiants
pubmed: 30549248
doi: 10.1002/cam4.1914
pmc: PMC6346266
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-310Informations de copyright
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2003 Feb 13;348(7):593-600
pubmed: 12584367
N Engl J Med. 2005 Sep 8;353(10):999-1007
pubmed: 16148285
J Clin Oncol. 2003 Sep 15;21(18):3431-9
pubmed: 12885835
Cancer Med. 2016 Jun;5(6):997-1003
pubmed: 26999817
Circulation. 2009 Aug 11;120(6):502-9
pubmed: 19635967
Basic Res Cardiol. 2004 Jan;99(1):61-8
pubmed: 14685707
Neoplasia. 2009 Aug;11(8):771-9
pubmed: 19649207
J Clin Oncol. 1993 Jul;11(7):1208-15
pubmed: 8315419
Cancer Med. 2019 Jan;8(1):305-310
pubmed: 30549248
Circulation. 2006 Apr 18;113(15):1888-904
pubmed: 16618833
Blood. 2000 Feb 1;95(3):952-8
pubmed: 10648408
J Clin Oncol. 2000 Feb;18(3):487-97
pubmed: 10653864
Circ Res. 2001 Jul 6;89(1):E1-7
pubmed: 11440984
J Clin Oncol. 2001 Jul 1;19(13):3173-81
pubmed: 11432883
J Clin Oncol. 2012 Sep 20;30(27):3383-8
pubmed: 22869887
Leuk Lymphoma. 2008 Aug;49(8):1486-93
pubmed: 18608873
Blood. 2011 Jan 13;117(2):412-8
pubmed: 20858859
JAMA. 2003 Dec 3;290(21):2831-7
pubmed: 14657067
Microvasc Res. 2010 May;79(3):217-23
pubmed: 20085777
JAMA Intern Med. 2015 Jun;175(6):1007-17
pubmed: 25915855
Circulation. 2004 Nov 9;110(19):3136-42
pubmed: 15520325
Eur J Cardiothorac Surg. 2010 Apr;37(4):758-63
pubmed: 19896859
J Clin Oncol. 2002 Apr 15;20(8):2101-8
pubmed: 11956271
J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):284-287
pubmed: 23592145
J Natl Cancer Inst. 2012 Mar 7;104(5):357-70
pubmed: 22312134
Circ Res. 2004 Aug 20;95(4):343-53
pubmed: 15321944
Cell. 2006 Jan 13;124(1):175-89
pubmed: 16413490
Eur J Prev Cardiol. 2014 Sep;21(9):1153-62
pubmed: 23598596
Br J Haematol. 2011 Jul;154(1):23-31
pubmed: 21539537